Persister development by Borrelia burgdorferi populations in vitro

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6288-6295

  Caskey, John R ^a   Embers, Monica E ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; ANTIINFECTIVE AGENT; CULTURE MEDIUM;

ABSORPTION LAG TIME; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BORRELIA BURGDORFERI; CELL DENSITY; CELL GROWTH; CELL SURVIVAL; DRUG RESPONSE; EFFECTIVE CONCENTRATION; GROWTH CURVE; GROWTH INHIBITION; GROWTH RATE; IN VITRO STUDY; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POPULATION DENSITY; POPULATION GROWTH; PRIORITY JOURNAL; ADAPTATION; BACTERIAL LOAD; CHEMISTRY; CULTURE MEDIUM; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; STATISTICAL MODEL;

ADAPTATION, PHYSIOLOGICAL; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BORRELIA BURGDORFERI; CULTURE MEDIA; DOXYCYCLINE; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL;

EID: 84942923212     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00883-15     Document Type: Article

References (58)

1. Bigger JW. 1944. Treatment of staphylococcal infections with penicillin. Lancet 244:497-500. http://dx.doi.org/10.1016/S0140-6736 (00) 74210-3.
2. Demerec M. 1948. Origin of bacterial resistance to antibiotics. J Bacteriol 56:63-74.
3. Tuomanen E, Tomasz A. 1990. Mechanism of phenotypic tolerance of nongrowing pneumococci to beta-lactam antibiotics. Scand J Infect Dis Suppl 74:102-112.
4. Tuomanen E, Durack DT, Tomasz A. 1986. Antibiotic tolerance among clinical isolates of bacteria. Antimicrob Agents Chemother 30:521-527. http://dx.doi.org/10.1128/AAC.30.4.521.
5. Tuomanen E. 1986. Phenotypic tolerance: the search for beta-lactam antibiotics that kill nongrowing bacteria. Rev Infect Dis 8(Suppl 3):S279-S291.
6. Lewis K. 2010. Persister cells. Annu Rev Microbiol 64:357-372. http://dx.doi.org/10.1146/annurev. micro.112408.134306.
7. Lewis K. 2012. Persister cells: molecular mechanisms related to antibiotic tolerance. Handb Exp Pharmacol 211:121-133. http://dx.doi.org/101007/978-3-642-28951-4-8.
8. Tuomanen E, Schwartz J, Sande S. 1990. The vir locus affects the response of Bordetella pertussis to antibiotics: phenotypic tolerance and control of autolysis. J Infect Dis 162:560-563. http://dx.doi.org/10.1093/infdis/162.2.560.
9. Wiuff C, Zappala RM, Regoes RR, Garner KN, Baquero F, Levin BR. 2005. Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob Agents Chemother 49:1483-1494. http://dx.doi.org/10.1128/AAC.49.4.1483-1494.2005.
10. Pal U, Dai J, Li X, Neelakanta G, Luo P, Kumar M, Wang P, Yang X, Anderson JF, Fikrig E. 2008. A differential role for BB0365 in the persistence of Borrelia burgdorferi in mice and ticks. J Infect Dis 197:148-155. http://dx.doi.org/10.1086/523764.
11. Li X, Pal U, Ramamoorthi N, Liu X, Desrosiers DC, Eggers CH, Anderson JF, Radolf JD, Fikrig E. 2007. The Lyme disease agent Borrelia burgdorferi requires BB0690, a Dps homologue, to persist within ticks. Mol Microbiol 63:694-710.
12. Embers ME, Barthold SW. 2012. Borrelia burgdorferi persistence postantibiotic treatment, p 229-257. In Embers ME (ed), The pathogenic spirochetes: strategies for evasion of host immunity and persistence. Springer, New York, NY.
13. Thattai M, van Oudenaarden A. 2004. Stochastic gene expression in fluctuating environments. Genetics 167:523-530. http://dx.doi.org/10.1534/genetics.167.1.523.
14. Elowitz MB, Levine AJ, Siggia ED, Swain PS. 2002. Stochastic gene expression in a single cell. Science 297:1183-1186. http://dx.doi.org/10.1126/science.1070919.
15. Avery SV. 2006. Microbial cell individuality and the underlying sources of heterogeneity. Nat Rev Microbiol 4:577-587. http://dx.doi.org/10.1038/nrmicro1460.
16. Barthold SW, Hodzic E, Imai DM, Feng S, Yang X, Luft BJ. 2010. Ineffectiveness of tigecycline against persistent Borrelia burgdorferi. Antimicrob Agents Chemother 54:643-651. http://dx.doi.org/10.1128/AAC.00788-09.
17. Embers ME, Barthold SW, Borda JT, Bowers L, Doyle L, Hodzic E, Jacobs MB, Hasenkampf NR, Martin DS, Narasimhan S, Phillippi-Falkenstein KM, Purcell JE, Ratterree MS, Philipp MT. 2012. Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS One 7:e29914. http://dx.doi.org/10.1371/journal.pone.0029914.
18. Yang X, Nguyen A, Qiu D, Luft BJ. 2009. In vitro activity of tigecycline against multiple strains of Borrelia burgdorferi. J Antimicrob Chemother 63:709-712. http://dx.doi.org/10.1093/jac/dkn551.
19. Chopra I, Roberts M. 2001. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:232-260. http://dx.doi.org/10.1128/MMBR.65.2.232-260.2001.
20. Yotsuji A, Mitsuyama J, Hori R, Yasuda T, Saikawa I, Inoue M, Mitsuhashi S. 1988. Mechanism of action of cephalosporins and resistance caused by decreased affinity for penicillin-binding proteins in Bacteroides fragilis. Antimicrob Agents Chemother 32:1848-1853. http://dx.doi.org/10.1128/AAC.32.12.1848.
21. Dattwyler RJ, Luft BJ, Kunkel MJ, Finkel MF, Wormser GP, Rush TJ, Grunwaldt E, Agger WA, Franklin M, Oswald D, Cockey L, Maladorno D. 1997. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med 337:289-294. http://dx.doi.org/10.1056/NEJM199707313370501.
22. Ogrinc K, Logar M, Lotric-Furlan S, Cerar D, Ruzic-Sabljic E, Strle F. 2006. Doxycycline versus ceftriaxone for the treatment of patients with chronic Lyme borreliosis. Wien Klin Wochenschr 118:696-701. http://dx.doi.org/10.1007/s00508-006-0698-7.
23. Feng J, Wang T, Shi W, Zhang S, Sullivan D, Auwaerter PG, Zhang Y. 2014. Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library. Emerg Microbe Infect 3:e49. http://dx.doi.org/10.1038/emi.2014.53.
24. Iyer R, Mukherjee P, Wang K, Simons J, Wormser GP, Schwartz I. 2013. Detection of Borrelia burgdorferi nucleic acids after antibiotic treatment does not confirm viability. J Clin Microbiol 51:857-862. http://dx.doi.org/10.1128/JCM.02785-12.
25. Ates L, Hanssen-Hubner C, Norris DE, Richter D, Kraiczy P, Hunfeld KP. 2010. Comparison of in vitro activities of tigecycline, doxycycline, and tetracycline against the spirochete Borrelia burgdorferi. Ticks Tick Borne Dis 1:30-34. http://dx.doi.org/10.1016/j.ttbdis.2009.11.004.
26. Hodzic E, Feng S, Holden K, Freet KJ, Barthold SW. 2008. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob Agents Chemother 52:1728-1736. http://dx.doi.org/10.1128/AAC.01050-07.
27. Sicklinger M, Wienecke R, Neubert U. 2003. In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto. J Clin Microbiol 41:1791-1793. http://dx.doi.org/10.1128/JCM.41.4.1791-1793.2003.
28. Purser JE, Norris SJ. 2000. Correlation between plasmid content and infectivity in Borrelia burgdorferi. Proc Natl Acad Sci U S A 97:13865-13870. http://dx.doi.org/10.1073/pnas.97.25.13865.
29. Zückert WR. 2005. Laboratory maintenance of Borrelia burgdorferi. Curr Protoc Microbiol Chapter 12: Unit 12C.1. http://dx.doi.org/10.1002/9780471729259.mc12c01s4.
30. Barbour AG. 1984. Isolation and cultivation of Lyme disease spirochetes. Yale J Biol Med 57:521-525.
31. Seshu J, Boylan JA, Gherardini FC, Skare JT. 2004. Dissolved oxygen levels alter gene expression and antigen profiles in Borrelia burgdorferi. Infect Immun 72:1580-1586. http://dx.doi.org/10.1128/IAI.72.3.1580-1586.2004.
32. Hunfeld KP, Ruzic-Sabljic E, Norris DE, Kraiczy P, Strle F. 2005. In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob Agents Chemother 49:1294-1301. http://dx.doi.org/10.1128/AAC.49.4.1294-1301.2005.
33. Sharma B, Brown AV, Matluck NE, Hu LT, Lewis K. 26 May 2015. Borrelia burgdorferi, the causative agent of Lyme disease, forms drugtolerant persister cells. Antimicrob Agents Chemother http://dx.doi.org/10.1128/aac.00864-15.
34. Kargi F. 2009. Re-interpretation of the logistic equation for batch microbial growth in relation to Monod kinetics. Lett Appl Microbiol 48:398-401. http://dx.doi.org/10.1111/j.1472-765X.2008.02537.x.
35. Stanek G, Baradaran-Dilmaghani R. 1996. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. Infection 24:60-63. http://dx.doi.org/10.1007/BF01780660.
36. Knowles DJ, Foloppe N, Matassova NB, Murchie AI. 2002. The bacterial ribosome, a promising focus for structure-based drug design. Curr Opin Pharmacol 2:501-506. http://dx.doi.org/10.1016/S1471-4892 (02) 00205-9.
37. Lewis K. 2008. Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 322:107-131.
38. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. 2004. Bacterial persistence as a phenotypic switch. Science 305:1622-1625. http://dx.doi.org/10.1126/science.1099390.
39. Lewis K. 2007. Persister cells, dormancy and infectious disease. Nat Rev Microbiol 5:48-56. http://dx.doi.org/10.1038/nrmicro1557.
40. Codling EA, Plank MJ, Benhamou S. 2008. Random walk models in biology. J R Soc Interface 5:813-834. http://dx.doi.org/10.1098/rsif.2008.0014.
41. Dörr T, Vulic M, Lewis K. 2010. Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol 8:e1000317. http://dx.doi.org/10.1371/journal.pbio.1000317.
42. Phillips I, Culebras E, Moreno F, Baquero F. 1987. Induction of the SOS response by new 4-quinolones. J Antimicrob Chemother 20:631-638. http://dx.doi.org/10.1093/jac/20.5.631.
43. Jõers A, Kaldalu N, Tenson T. 2010. The frequency of persisters in Escherichia coli reflects the kinetics of awakening from dormancy. J Bacteriol 192:3379-3384. http://dx.doi.org/10.1128/JB.00056-10.
44. Hansen S, Lewis K, Vulic M. 2008. Role of global regulators and nucleotide metabolism in antibiotic tolerance in Escherichia coli. Antimicrob Agents Chemother 52:2718-2726. http://dx.doi.org/10.1128/AAC.00144-08.
45. Epstein SS. 2009. Microbial awakenings. Nature 457:1083. http://dx.doi.org/10.1038/4571083a.
46. Rainey PB, Beaumont HJ, Ferguson GC, Gallie J, Kost C, Libby E, Zhang XX. 2011. The evolutionary emergence of stochastic phenotype switching in bacteria. Microb Cell Fact 10(Suppl 1):S14. http://dx.doi.org/10.1186/1475-2859-10-S1-S14.
47. Barthold SW, Persing DH, Armstrong AL, Peeples RA. 1991. Kinetics of Borrelia burgdorferi dissemination and evolution of disease after intradermal inoculation of mice. Am J Pathol 139:263-273.
48. Feng J, Auwaerter PG, Zhang Y. 2015. Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline. PLoS One 10:e0117207. http://dx.doi.org/10.1371/journal.pone.0117207.
49. Terekhova D, Sartakova ML, Wormser GP, Schwartz I, Cabello FC. 2002. Erythromycin resistance in Borrelia burgdorferi. Antimicrob Agents Chemother 46:3637-3640. http://dx.doi.org/10.1128/AAC.46.11.3637-3640.2002.
50. Hodzic E, Imai D, Feng S, Barthold SW. 2014. Resurgence of persisting non-cultivable Borrelia burgdorferi following antibiotic treatment in mice. PLoS One 9:e86907. http://dx.doi.org/10.1371/journal.pone.0086907.
51. Bockenstedt LK, Mao J, Hodzic E, Barthold SW, Fish D. 2002. Detection of attenuated, noninfectious spirochetes in Borrelia burgdorferi-infected mice after antibiotic treatment. J Infect Dis 186:1430-1437. http://dx.doi.org/10.1086/345284.
52. Straubinger RK, Summers BA, Chang YF, Appel MJ. 1997. Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J Clin Microbiol 35:111-116.
53. Embers ME, Ramamoorthy R, Philipp MT. 2004. Survival strategies of Borrelia burgdorferi, the etiologic agent of Lyme disease. Microbes Infect 6:312-318.
54. Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton D, Levy L, Wall D, McCall J, Kosinski M, Weinstein A. 2001. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 345:85-92. http://dx.doi.org/10.1056/NEJM200107123450202.
55. Nguyen D, Joshi-Datar A, Lepine F, Bauerle E, Olakanmi O, Beer K, McKay G, Siehnel R, Schafhauser J, Wang Y, Britigan BE, Singh PK. 2011. Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. Science 334:982-986. http://dx.doi.org/10.1126/science.1211037.
56. Wu Y, Vulic M, Keren I, Lewis K. 2012. Role of oxidative stress in persister tolerance. Antimicrob Agents Chemother 56:4922-4926. http://dx.doi.org/10.1128/AAC.00921-12.
57. Balaban NQ, Gerdes K, Lewis K, McKinney JD. 2013. A problem of persistence: still more questions than answers? Nat Rev Microbiol 11:587-591. http://dx.doi.org/10.1038/nrmicro3076.
58. Piesman J, Oliver JR, Sinsky RJ. 1990. Growth kinetics of the Lyme disease spirochete (Borrelia Burgdorferi) in vector ticks (Ixodes Dammini). Am J Trop Med Hyg 42:352-357.